TALVEY

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Lithuania, Romania, UK.

Active ingredients

The drug TALVEY contains one active pharmaceutical ingredient (API):

1	Talquetamab UNII 4W3KFI3TN3 - TALQUETAMAB
	Talquetamab is a immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) bispecific antibody directed against GPRC5D and the CD3 receptor on T Cells. Talquetamab promotes enhanced T cell-mediated cytotoxicity through recruitment of CD3-expressing T cells to GPRC5D-expressing cells. Based on the expression of GPRC5D on plasma cells with minimal to no expression detected on B cells and B cell precursors, talquetamab targets multiple myeloma cells particularly.
	Read more about Talquetamab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TALVEY Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX29		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX29

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3044999, 3045002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	194469, 453194
FR	Base de données publique des médicaments	66105564, 66226822
IT	Agenzia del Farmaco	050827017, 050827029
LT	Valstybinė vaistų kontrolės tarnyba	1097699, 1097700
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69749001, W69750001
US	FDA, National Drug Code	57894-469, 57894-470